RJA
NVCR icon

Raymond James & Associates’s NovoCure NVCR Stock Holding History

Raymond James & Associates’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,250
Closed -$342K – 3892
2023
Q2 		$342K Sell
8,250
-7,578
-48% -$471K ﹤0.01% 3159
2023
Q1 		$952K Sell
15,828
-726
-4% -$58K ﹤0.01% 2482
2022
Q4 		$1.21M Sell
16,554
-1,140
-6% -$85.8K ﹤0.01% 2317
2022
Q3 		$1.34M Sell
17,694
-792
-4% -$61.8K ﹤0.01% 2218
2022
Q2 		$1.28M Sell
18,486
-3,327
-15% -$251K ﹤0.01% 2290
2022
Q1 		$1.81M Sell
21,813
-854
-4% -$62.9K ﹤0.01% 2199
2021
Q4 		$1.7M Buy
22,667
+3,463
+18% +$348K ﹤0.01% 2281
2021
Q3 		$2.23M Buy
19,204
+824
+4% +$125K ﹤0.01% 2020
2021
Q2 		$4.08M Buy
18,380
+1,777
+11% +$346K ﹤0.01% 1625
2021
Q1 		$2.19M Sell
16,603
-40,215
-71% -$6.36M ﹤0.01% 1949
2020
Q4 		$9.83M Buy
56,818
+37,836
+199% +$5.18M 0.01% 958
2020
Q3 		$2.11M Sell
18,982
-5,726
-23% -$458K ﹤0.01% 1733
2020
Q2 		$1.47M Buy
24,708
+7,550
+44% +$497K ﹤0.01% 1915
2020
Q1 		$1.16M Sell
17,158
-1,479
-8% -$117K ﹤0.01% 1883
2019
Q4 		$1.57M Buy
18,637
+2,897
+18% +$234K ﹤0.01% 1983
2019
Q3 		$1.18M Buy
15,740
+10,637
+208% +$851K ﹤0.01% 2100
2019
Q2 		$323K Buy
5,103
+201
+4% +$10.2K ﹤0.01% 2963
2019
Q1 		$236K Sell
4,902
-2,211
-31% -$106K ﹤0.01% 3125
2018
Q4 		$238K Buy
7,113
+1,714
+32% +$62.7K ﹤0.01% 3006
2018
Q3 		$283K Buy
+5,399
New +$215K ﹤0.01% 3069

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Raymond James & Associates's NVCR Position: Q3 2023 in Review

Raymond James & Associates sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 8,250 shares — an estimated $342K sold.

Raymond James & Associates first reported a position in NVCR in Q3 2018 and held it in 20 quarters. The position peaked at $9.83M in Q4 2020. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

  • Raymond James & Associates reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
  • Raymond James & Associates sold 8,250 NovoCure shares in Q3 2023, an estimated $342K.
  • Raymond James & Associates first reported a position in NovoCure in Q3 2018 and held it in 20 quarters.
  • Raymond James & Associates's NovoCure position peaked at $9.83M in Q4 2020.
  • 226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.